ClinicalTrials.gg
CompletedNCT00490139ALTTOUpdated Mar 21, 2025Results posted

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

A Phase 3 interventional study of Lapatinib and Trastuzumab in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Completed at 925 sites in 44 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,381
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.

Enrollment
Largest of 114
8,381 · median 35
Started
2007
with 15 others
Phase 3
18 of 114
none open now
Registered
43rd of 114
by date
Lead sponsor
15 of 114
Novartis Pharmaceuticals

Among the 114 studies testing lapatinib in Breast Neoplasms, this one has the largest enrollment, is one of 16 that started in 2007, is one of 18 in phase 3, and was the 43rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About lapatinib

Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 114 studies testing lapatinib in Breast Neoplasms as a file.
02

Study summary

This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone, compared to Trastuzumab alone in the adjuvant treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive early breast cancer.

Read the detailed description

Treatment allocation was stratified by blocked randomization, with three stratification factors:

  • Hormone receptor status: Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) positive versus both negative.
  • Axillary lymph node involvement: not assessed because of neoadjuvant chemotherapy versus node negative versus 1-3 positive nodes versus 4 or more positive nodes.
  • Timing of adjuvant chemotherapy: concurrently with taxanes and targeted therapy (Design 2) and concurrently with non-anthracycline-based platinum chemotherapy and targeted therapy (Design 2B) versus all other chemotherapy completed before randomization (Design 1). Treatments delivered differed according to the timing and type of adjuvant chemotherapy.

The primary objective of this study was to compare disease-free survival (DFS) in subjects with HER2 overexpressing and/or amplified breast cancer randomized to trastuzumab for one year versus lapatinib for one year versus trastuzumab (12 or 18 weeks, according to assigned design) followed by a six week treatment-free interval followed by lapatinib (28 or 34 weeks, according to assigned design) versus trastuzumab in combination with lapatinib for one year (52 weeks).

Secondary objectives included treatment comparisons with respect to overall survival, time to recurrence, time to distant recurrence, safety and tolerability, and incidence of brain metastasis.

Based on the recommendation of the Independent Data Monitoring Committee (IDMC) at the first interim analysis (18-Aug-2011), the Lapatinib alone arm was discontinued prior to primary analysis due to futility. The IDMC also stated that the other three arms (trastuzumab alone, sequential trastuzumab/lapatinib arm and the combination arm) could continued as planned with no changes.

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • Adjuvant
  • ErbB2-overexpressing
  • Early stage breast cancer
  • HER2/neu gene amplified
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients >= 18 years of age with confirmed, non-, operable and over expression/amplification of (3+ by IHC and/or FISH positive) primary breast cancer, treated with definitive surgery, with baseline >= 50%, known hormone receptor status (ER/PgR or ER alone) and performance status =\< 1, were included.
  • For Designs 1 and 2: Patients must have had received at least four cycles of an approved anthracycline-based (neo-) chemotherapy regimen or a protocol specified exception.
  • Approved, signed written obtained prior to any study specific screening procedures.

Key Exclusion Criteria:

  • History of any prior (ipsi- and/or contralateral) invasive breast carcinoma, past (less than 10 years) or current history of malignant neoplasms, any clinically staged T4 tumor, or bilateral tumors.
  • Concurrent anti-cancer treatment, except hormonal therapy or radiotherapy for the present breast cancer;
  • Patients with positive or suspicious internal mammary nodes identified by sentinel node technique, which had not been irradiated or would not be irradiated, or patients with supraclavicular lymph node involvement.
  • Any prior anti-HER therapy, which includes agents that target other members of the HER family of receptors, e.g. gefitinib (Iressa)
  • (Neo-) or adjuvant chemotherapy using peripheral stem cell or bone marrow stem cell support;
  • Serious cardiac illness or medical conditions.
  • Any of the following abnormal laboratory tests immediately prior to randomization:

    1. Serum total >1.5 x (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\<2 x ULN) was allowed;
    2. Alanine amino transferase () or aspartate amino transferase (AST) >2.5 x ULN;
    3. Alkaline phosphatase (ALP) >2.5 x ULN;
    4. Serum creatinine >2.0 x ULN;
    5. Total white blood cell count (WBC) \<2.5 x 10\^9/L;
    6. \<1.5 x 10\^9/L;
    7. \<100 x 10\^9/L.
  • Women of and male patients with partners of childbearing potential, who are unable or unwilling to use adequate measures during study treatment, and pregnant or lactating women.
  • Concomitant use of inhibitors or inducers.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,381 participants (actual)

Study arms

  • Experimental
    Lapatinib plus Trastuzumab

    Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total). Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total). Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total).

    Drug: Lapatinib · Biological: Trastuzumab

  • Experimental
    Trastuzumab followed by Lapatinib

    Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total). Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total). Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total).

    Drug: Lapatinib · Biological: Trastuzumab

  • Experimental
    Lapatinib

    Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks. Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total). Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total).

    Drug: Lapatinib

  • Active comparator
    Trastuzumab

    Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks. Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total). Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total).

    Biological: Trastuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) at the Primary Analysis

    Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85, 80 and 75 percent) of participants who had disease free survival for the indicated years.

    Time frame: From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause (median follow-up of 4.5 years)

Secondary outcomes

  1. Disease-Free Survival (DFS) at the 10-Year Follow-Up

    Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85 and 80 percent) of participants who had disease free survival for the indicated years.

    Time frame: From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause, assessed up to approximately 10 years

  2. Overall Survival (OS) at the Primary Analysis

    Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 97, 96, 95 and 90 percent) of participants who survived for the indicated years.

    Time frame: From randomization until death due to any cause (median follow-up of 4.5 years)

  3. Overall Survival (OS) at the 10-Year Follow-Up

    Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 95 and 90 percent) of participants who survived for the indicated years.

    Time frame: From randomization until death due to any cause, assessed up to approximately 10 years

  4. Analysis of Time to Recurrence (TTR)

    Time to Recurrence (TTR) was defined as the the time from randomization to breast cancer recurrence, ignoring second primary cancers (including contralateral breast cancers and non-breast second malignancies) and counting deaths without recurrence as a competing risk.

    Time frame: From randomization until the date of the first occurrence of a disease recurrence, assessed up to approximately 10 years

  5. Analysis of Time to Distant Recurrence (TTDR)

    Time to Distant Recurrence (TTDR) was defined as the the time from randomization to first distant breast cancer recurrence, ignoring locoregional recurrences and second primary cancers, (including contralateral breast cancers and non-breast second malignancies ) and counting deaths without recurrence as a competing risk.

    Time frame: From randomization until the date of the first occurrence of distant recurrence, assessed up to approximately 10 years

  6. Analysis of Time to Central Nervous System (CNS) Recurrence

    Time to Central Nervous System (CNS) recurrence was defined as the time from randomization to first CNS recurrence. Both brain metastasis and meningitis carcinomatosa were considered.

    Time frame: From randomization until the first central nervous system recurrence, assessed up to approximately 10 years

  7. Cumulative Incidence of Brain Metastases

    The cumulative incidence of brain metastases as the first site of breast cancer recurrence among treatment arms was assessed using a hierarchy of primary type and location of first DFS event in cases where more than one event was identified simultaneously. Because diagnostic procedures for different types of recurrence could not be performed on exactly the same day, any diagnoses noted within a two month (60 day) period of the first reported event was considered as identified simultaneously for purposes of defining the type of the first event and the date of event was be regarded as the earliest of the relevant events.

    Time frame: From randomization until the date of the first occurrence of a disease recurrence, assessed up to approximately 10 years

07

Results

Posted Aug 18, 2014

Participant flow

This study was conducted in 969 centers in 44 countries worldwide.

Participant flow — Overall Study
MilestoneLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
Started2093209121002097
Safety population2061207620562076
Completed1132118411791192
Not completed961907921905
Withdrew: Lost to follow-up249216205229
Withdrew: Withdrawal by subject333322396295
Withdrew: Patient did not sign icf 12169176139167
Withdrew: Data unavailable due to regulatory issues98968595
Withdrew: Data unavailable due to lapsed ethical consent14131414
Withdrew: Other reasons as defined per protocol988482105

Outcome measures

PrimaryDisease-Free Survival (DFS) at the Primary Analysis

Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85, 80 and 75 percent) of participants who had disease free survival for the indicated years.

Time frame:
From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause (median follow-up of 4.5 years)
Reported as:
Number · Years
Disease-Free Survival (DFS) at the Primary Analysis
YearsLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
95th Percentile1.91.31.01.5
90th Percentile3.22.81.82.6
85th Percentile5.14.82.84.2
80th Percentile6.1NANA5.6
75th Percentile6.1NANANA
Statistical analysis
  • Lapatinib Plus Trastuzumab vs Trastuzumab · Log Rank · p = 0.048 · Hazard ratio (hr): 0.84 · 95% CI 0.71 to 1.00The estimate of the treatment hazard ratio (lap plus tras versus tras) was based on the Cox proportional hazards model adjusting for the stratification factors of chemotherapy timing, hormone receptor status, and axillary lymph node status.
  • Trastuzumab Followed by Lapatinib vs Trastuzumab · Log Rank · p = 0.610 · Hazard ratio (hr): 0.96 · 95% CI 0.81 to 1.13The estimate of the treatment hazard ratio (lap plus tras versus tras) was based on the Cox proportional hazards model adjusting for the stratification factors of chemotherapy timing, hormone receptor status, and axillary lymph node status.
SecondaryDisease-Free Survival (DFS) at the 10-Year Follow-Up

Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85 and 80 percent) of participants who had disease free survival for the indicated years.

Time frame:
From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause, assessed up to approximately 10 years
Reported as:
Number · Years
Disease-Free Survival (DFS) at the 10-Year Follow-Up
YearsLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
95th Percentile1.891.27—1.49
90th Percentile3.212.80—2.63
85th Percentile5.924.85—4.43
80th Percentile8.999.18—7.42
Statistical analysis
  • Lapatinib Plus Trastuzumab vs Trastuzumab · Hazard ratio (hr): 0.887 · 95% CI 0.77 to 1.02The estimate of the treatment hazard ratio (lap plus tras versus tras) was based on the Cox proportional hazards model adjusting for the stratification factors of chemotherapy timing, hormone receptor status, and axillary lymph node status.
  • Trastuzumab Followed by Lapatinib vs Trastuzumab · Hazard ratio (hr): 0.914 · 95% CI 0.80 to 1.05The estimate of the treatment hazard ratio (lap plus tras versus tras) was based on the Cox proportional hazards model adjusting for the stratification factors of chemotherapy timing, hormone receptor status, and axillary lymph node status.
SecondaryOverall Survival (OS) at the Primary Analysis

Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 97, 96, 95 and 90 percent) of participants who survived for the indicated years.

Time frame:
From randomization until death due to any cause (median follow-up of 4.5 years)
Reported as:
Number · Years
Overall Survival (OS) at the Primary Analysis
YearsLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
99th Percentile1.71.2—1.7
98th Percentile2.21.6—2.1
97th Percentile2.82.2—2.6
96th Percentile3.42.9—3.0
95th Percentile3.93.7—3.6
90th PercentileNANA—5.9
Statistical analysis
  • Lapatinib Plus Trastuzumab vs Trastuzumab · Log Rank · p = 0.078 · Hazard ratio (hr): 0.80 · 95% CI 0.62 to 1.03The estimate of the treatment hazard ratio (lap plus tras versus tras) was based on the Cox proportional hazards model adjusting for the stratification factors of chemotherapy timing, hormone receptor status, and axillary lymph node status.
  • Trastuzumab Followed by Lapatinib vs Trastuzumab · Log Rank · p = 0.433 · Hazard ratio (hr): 0.91 · 95% CI 0.71 to 1.16The estimate of the treatment hazard ratio (tras followed by lap versus tras) was based on the Cox proportional hazards model adjusting for the stratification factors of chemotherapy timing, hormone receptor status, and axillary lymph node status.
SecondaryOverall Survival (OS) at the 10-Year Follow-Up

Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 95 and 90 percent) of participants who survived for the indicated years.

Time frame:
From randomization until death due to any cause, assessed up to approximately 10 years
Reported as:
Number · Years
Overall Survival (OS) at the 10-Year Follow-Up
YearsLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
99th Percentile1.681.17—1.75
98th Percentile2.191.60—2.07
95th Percentile3.923.52—3.65
90th Percentile8.318.49—6.72
Statistical analysis
  • Lapatinib Plus Trastuzumab vs Trastuzumab · Hazard ratio (hr): 0.853 · 95% CI 0.70 to 1.03The estimate of the treatment hazard ratio (lap plus tras versus tras) was based on the Cox proportional hazards model adjusting for the stratification factors of chemotherapy timing, hormone receptor status, and axillary lymph node status.
  • Trastuzumab Followed by Lapatinib vs Trastuzumab · Hazard ratio (hr): 0.863 · 95% CI 0.71 to 1.04The estimate of the treatment hazard ratio (tras followed by lap versus tras) was based on the Cox proportional hazards model adjusting for the stratification factors of chemotherapy timing, hormone receptor status, and axillary lymph node status.
SecondaryAnalysis of Time to Recurrence (TTR)

Time to Recurrence (TTR) was defined as the the time from randomization to breast cancer recurrence, ignoring second primary cancers (including contralateral breast cancers and non-breast second malignancies) and counting deaths without recurrence as a competing risk.

Time frame:
From randomization until the date of the first occurrence of a disease recurrence, assessed up to approximately 10 years
Reported as:
Count of participants · Participants
Analysis of Time to Recurrence (TTR)
ParticipantsLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
Local, regional, or distant recurrence243275—298
Death as a competing risk4338—46
Censored18071778—1753
Statistical analysis
  • Lapatinib Plus Trastuzumab vs Trastuzumab · Hazard ratio (hr): 0.811 · 95% CI 0.68 to 0.96
  • Trastuzumab Followed by Lapatinib vs Trastuzumab · Hazard ratio (hr): 0.930 · 95% CI 0.79 to 1.10
SecondaryAnalysis of Time to Distant Recurrence (TTDR)

Time to Distant Recurrence (TTDR) was defined as the the time from randomization to first distant breast cancer recurrence, ignoring locoregional recurrences and second primary cancers, (including contralateral breast cancers and non-breast second malignancies ) and counting deaths without recurrence as a competing risk.

Time frame:
From randomization until the date of the first occurrence of distant recurrence, assessed up to approximately 10 years
Reported as:
Count of participants · Participants
Analysis of Time to Distant Recurrence (TTDR)
ParticipantsLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
Distant recurrence213238—250
Death as a competing risk4541—54
Censored18351812—1793
Statistical analysis
  • Lapatinib Plus Trastuzumab vs Trastuzumab · Hazard ratio (hr): 0.852 · 95% CI 0.71 to 1.02
  • Trastuzumab Followed by Lapatinib vs Trastuzumab · Hazard ratio (hr): 0.968 · 95% CI 0.81 to 1.16
SecondaryAnalysis of Time to Central Nervous System (CNS) Recurrence

Time to Central Nervous System (CNS) recurrence was defined as the time from randomization to first CNS recurrence. Both brain metastasis and meningitis carcinomatosa were considered.

Time frame:
From randomization until the first central nervous system recurrence, assessed up to approximately 10 years
Reported as:
Count of participants · Participants
Analysis of Time to Central Nervous System (CNS) Recurrence
ParticipantsLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
CNS recurrence9191—95
Death as a competing risk114117—142
Censored18881883—1860
Statistical analysis
  • Lapatinib Plus Trastuzumab vs Trastuzumab · Hazard ratio (hr): 0.986 · 95% CI 0.74 to 1.31
  • Trastuzumab Followed by Lapatinib vs Trastuzumab · Hazard ratio (hr): 0.980 · 95% CI 0.74 to 1.31
SecondaryCumulative Incidence of Brain Metastases

The cumulative incidence of brain metastases as the first site of breast cancer recurrence among treatment arms was assessed using a hierarchy of primary type and location of first DFS event in cases where more than one event was identified simultaneously. Because diagnostic procedures for different types of recurrence could not be performed on exactly the same day, any diagnoses noted within a two month (60 day) period of the first reported event was considered as identified simultaneously for purposes of defining the type of the first event and the date of event was be regarded as the earliest of the relevant events.

Time frame:
From randomization until the date of the first occurrence of a disease recurrence, assessed up to approximately 10 years
Reported as:
Count of participants · Participants
Cumulative Incidence of Brain Metastases
ParticipantsLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
Cumulative Incidence of Brain Metastases5052—48
Post-hocAll Collected Deaths

Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication. On-treatment deaths were collected from first dose of study medication to 30 days after last dose of study medication (on-treatment), up to approximately 56 weeks. Deaths were collected in the post treatment survival follow up from 31 days after last dose of study medication until the end of the study, up to approximately 10 years.

Time frame:
Pre-treatment deaths: Up to 14 days prior to treatment. On-treatment deaths: Up to 56 weeks. Post-treatment deaths: up to 10 years.
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumab
Pre-treatment deaths1212
On-treatment deaths65123
Post-treatment deaths189190250228
All deaths196197263233

Adverse events

Collected over Adverse Events (AEs) were collected from first dose of study medication until the last dose plus 30 days post-treat follow-up, assessed up to approximately 56 weeks. Deaths were recorded from study start date until end of survival follow-up phase (end of study), assessed up to approximately 10 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lapatinib Plus Trastuzumab7/2,093 (0.3%)379/2,061 (18.4%)1,930/2,061 (93.6%)
Trastuzumab Followed by Lapatinib7/2,091 (0.3%)299/2,076 (14.4%)1,862/2,076 (89.7%)
Lapatinib13/2,100 (0.6%)394/2,056 (19.2%)1,887/2,056 (91.8%)
Trastuzumab5/2,097 (0.2%)251/2,076 (12.1%)1,649/2,076 (79.4%)
Lapatinib Plus Trastuzumab (Post-Treatment)189/2,055 (9.2%)——
Trastuzumab Followed by Lapatinib (Post-Treatment)190/2,071 (9.2%)——
Lapatinib (Post-Treatment)250/2,044 (12.2%)——
Trastuzumab (Post-Treatment)228/2,073 (11%)——
Most frequent serious events
Showing 10 of 480
Most frequent serious events
EventLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumabLapatinib Plus Trastuzumab (Post-Treatment)Trastuzumab Followed by Lapatinib (Post-Treatment)Lapatinib (Post-Treatment)Trastuzumab (Post-Treatment)
HYPERTRANSAMINASAEMIAHepatobiliary disorders74/206155/207686/205611/2076————
DIARRHOEAGastrointestinal disorders53/20616/207644/20569/2076————
NEUTROPENIABlood and lymphatic system disorders37/206121/207636/205620/2076————
CARDIAC FAILURE CONGESTIVECardiac disorders24/20616/20767/205619/2076————
LEUKOPENIABlood and lymphatic system disorders20/20614/207613/20567/2076————
HYPERBILIRUBINAEMIAHepatobiliary disorders5/206112/207618/20561/2076————
PYREXIAGeneral disorders11/206116/207613/20565/2076————
CELLULITISInfections and infestations15/206114/20767/20565/2076————
PNEUMONIAInfections and infestations14/206111/20769/205610/2076————
ANAEMIABlood and lymphatic system disorders7/20616/207613/20567/2076————
Most frequent other events
Showing 10 of 50
Most frequent other events
EventLapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumabLapatinib Plus Trastuzumab (Post-Treatment)Trastuzumab Followed by Lapatinib (Post-Treatment)Lapatinib (Post-Treatment)Trastuzumab (Post-Treatment)
DIARRHOEAGastrointestinal disorders1516/20611039/20761278/2056399/2076————
RASHSkin and subcutaneous tissue disorders771/2061685/2076767/2056223/2076————
FATIGUEGeneral disorders511/2061515/2076443/2056439/2076————
ARTHRALGIAMusculoskeletal and connective tissue disorders340/2061348/2076320/2056451/2076————
NAUSEAGastrointestinal disorders393/2061393/2076381/2056285/2076————
HYPERTRANSAMINASAEMIAHepatobiliary disorders348/2061378/2076366/2056281/2076————
NAIL DISORDERSkin and subcutaneous tissue disorders359/2061272/2076294/2056220/2076————
PRURITUSSkin and subcutaneous tissue disorders316/2061268/2076334/2056134/2076————
EPISTAXISRespiratory, thoracic and mediastinal disorders319/2061213/2076244/2056165/2076————
DRY SKINSkin and subcutaneous tissue disorders262/2061244/2076280/205686/2076————

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumabTotal
Mean50.9 ± 10.2350.8 ± 10.3251.2 ± 10.1851.0 ± 10.2551.0 ± 10.24
Sex: Female, Male
Sex: Female, Male(Participants)Lapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumabTotal
Female20912086209820978372
Male25209
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumabTotal
American Indian or Alaska Native48454747187
Asian: Central/South107103110109429
Asian: East3113122993141236
Asian: Japanese33363343145
Asian: South East959210789383
Black or African American38304325136
Native Hawaiian or Other Pacific244515
White: Arabic53526269236
White: Caucasian13921402137213825548
Other Race1414231465
Unknown/Missing01001
Hormone Receptor (HR) Status
Hormone Receptor (HR) Status(Participants)Lapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumabTotal
Negative8908869038973576
Positive12031205119712004805
Timing of Chemotherapy
Timing of Chemotherapy(Participants)Lapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumabTotal
Sequential11551143116811474613
Concurrent9389489329503768
Axillary Lymph Node Status
Axillary Lymph Node Status(Participants)Lapatinib Plus TrastuzumabTrastuzumab Followed by LapatinibLapatinibTrastuzumabTotal
Not applicable (neoadjuvant chemotherapy)168170167181686
Node negative (no neoadjuvant chemotherapy)8458428418443372
1-3 positive nodes (no neoadjuvant chemotherapy)6176176206032457
>= 4 positive nodes (no neoadjuvant chemotherapy)4634624724691866
08

Study locations

925 sites
  • Novartis Investigative Site
    Mobile, Alabama 36608, United States
  • Novartis Investigative Site
    Anchorage, Alaska 99508, United States
  • Novartis Investigative Site
    Tucson, Arizona 85715, United States
  • Novartis Investigative Site
    Jonesboro, Arkansas 72401, United States
  • Novartis Investigative Site
    Duarte, California 91010, United States
  • Novartis Investigative Site
    Fairfield, California 94533, United States
  • Novartis Investigative Site
    La Jolla, California 92093-0987, United States
  • Novartis Investigative Site
    La Jolla, California 92093, United States
  • Novartis Investigative Site
    Loma Linda, California 92534, United States
  • Novartis Investigative Site
    Martinez, California 94553-3156, United States
  • Novartis Investigative Site
    Marysville, California 95901, United States
  • Novartis Investigative Site
    Mountain View, California 94040, United States
  • Novartis Investigative Site
    Oakland, California 94609, United States
  • Novartis Investigative Site
    Pleasanton, California 94588, United States
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    San Francisco, California 94110, United States
  • Novartis Investigative Site
    Aurora, Colorado 80012, United States
  • Novartis Investigative Site
    Boulder, Colorado 80301, United States
  • Novartis Investigative Site
    Colorado Springs, Colorado 80907, United States
  • Novartis Investigative Site
    Denver, Colorado 80210, United States
  • Novartis Investigative Site
    Denver, Colorado 80218, United States
  • Novartis Investigative Site
    Denver, Colorado 80220, United States
  • Novartis Investigative Site
    Fort Collins, Colorado 80524, United States
  • Novartis Investigative Site
    Fort Collins, Colorado 80528, United States
  • Novartis Investigative Site
    Thornton, Colorado 80229, United States
  • Novartis Investigative Site
    Wheat Ridge, Colorado 80033, United States
  • Novartis Investigative Site
    Hartford, Connecticut 06105, United States
  • Novartis Investigative Site
    New Haven, Connecticut 06520, United States
  • Novartis Investigative Site
    Dover, Delaware 19901, United States
  • Novartis Investigative Site
    Washington, District of Columbia 20007, United States
  • Novartis Investigative Site
    Washington, District of Columbia 20307, United States
  • Novartis Investigative Site
    Boca Raton, Florida 33486, United States
  • Novartis Investigative Site
    Fort Lauderdale, Florida 33308, United States
  • Novartis Investigative Site
    Fort Myers, Florida 33916, United States
  • Novartis Investigative Site
    Hollywood, Florida 33021, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32207, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32224, United States
  • Novartis Investigative Site
    Lakeland, Florida 33805, United States
  • Novartis Investigative Site
    Ocala, Florida 34474, United States
  • Novartis Investigative Site
    Orlando, Florida 32803, United States
  • Novartis Investigative Site
    Orlando, Florida 32806, United States
  • Novartis Investigative Site
    Weston, Florida 33331, United States
  • Novartis Investigative Site
    Athens, Georgia 30607, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30309, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30342, United States
  • Novartis Investigative Site
    Augusta, Georgia 30912, United States
  • Novartis Investigative Site
    Columbus, Georgia 31904, United States
  • Novartis Investigative Site
    Decatur, Georgia 30033, United States
  • Novartis Investigative Site
    Savannah, Georgia 31405, United States
  • Novartis Investigative Site
    Honolulu, Hawaii 96813, United States
  • Novartis Investigative Site
    Honolulu, Hawaii 96859, United States
  • Novartis Investigative Site
    Lihue, Hawaii 96766, United States
  • Novartis Investigative Site
    Boise, Idaho 83706, United States
  • Novartis Investigative Site
    Boise, Idaho 83712, United States
  • Novartis Investigative Site
    Chicago, Illinois 60611, United States
  • Novartis Investigative Site
    Evanston, Illinois 60201, United States
  • Novartis Investigative Site
    Harvey, Illinois 60426, United States
  • Novartis Investigative Site
    Kankakee, Illinois 60901, United States
  • Novartis Investigative Site
    Maywood, Illinois 60153, United States
  • Novartis Investigative Site
    Mount Vernon, Illinois 62864, United States
  • Novartis Investigative Site
    Oak Lawn, Illinois 60453-2699, United States
  • Novartis Investigative Site
    Ottawa, Illinois 61350, United States
  • Novartis Investigative Site
    Pekin, Illinois 61554, United States
  • Novartis Investigative Site
    Peoria, Illinois 61615, United States
  • Novartis Investigative Site
    Peru, Illinois 61354, United States
  • Novartis Investigative Site
    Princeton, Illinois 61356, United States
  • Novartis Investigative Site
    Rockford, Illinois 61104, United States
  • Novartis Investigative Site
    Rockford, Illinois 61114, United States
  • Novartis Investigative Site
    Skokie, Illinois 60077, United States
  • Novartis Investigative Site
    Springfield, Illinois 62781-0001, United States
  • Novartis Investigative Site
    Urbana, Illinois 61801, United States
  • Novartis Investigative Site
    Beech Grove, Indiana 46107, United States
  • Novartis Investigative Site
    Fort Wayne, Indiana 46815, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46202, United States
  • Novartis Investigative Site
    Kokomo, Indiana 46904, United States
  • Novartis Investigative Site
    Mishawaka, Indiana 46545, United States
  • Novartis Investigative Site
    Muncie, Indiana 47303, United States
  • Novartis Investigative Site
    South Bend, Indiana 46601, United States
  • Novartis Investigative Site
    South Bend, Indiana 46617, United States
  • Novartis Investigative Site
    Ames, Iowa 50010, United States
  • Novartis Investigative Site
    Bettendorf, Iowa 52722, United States
  • Novartis Investigative Site
    Cedar Rapids, Iowa 52402, United States
  • Novartis Investigative Site
    Des Moines, Iowa 50309, United States
  • Novartis Investigative Site
    Des Moines, Iowa 50314, United States
  • Novartis Investigative Site
    Mason City, Iowa, United States
  • Novartis Investigative Site
    Sioux City, Iowa 51101-1733, United States
  • Novartis Investigative Site
    Waterloo, Iowa 50702, United States
  • Novartis Investigative Site
    Chanute, Kansas 66720, United States
  • Novartis Investigative Site
    El Dorado, Kansas 67042, United States
  • Novartis Investigative Site
    Independence, Kansas 67301, United States
  • Novartis Investigative Site
    Lawrence, Kansas 66044, United States
  • Novartis Investigative Site
    Prairie Village, Kansas 66208, United States
  • Novartis Investigative Site
    Pratt, Kansas 67124, United States
  • Novartis Investigative Site
    Topeka, Kansas 66604, United States
  • Novartis Investigative Site
    Topeka, Kansas 66606, United States
  • Novartis Investigative Site
    Wichita, Kansas 67214, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40292, United States
  • Novartis Investigative Site
    Baton Rouge, Louisiana 70809, United States
  • Novartis Investigative Site
    New Orleans, Louisiana 70112, United States
  • Novartis Investigative Site
    New Orleans, Louisiana 70121, United States

Showing the first 100 of 925 sites across 44 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard KI, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni U, de Azambuja E. Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study. Br J Cancer. 2022 Nov;127(10):1799-1807. doi: 10.1038/s41416-022-01963-8. Epub 2022 Sep 1. PubMed 36050448 ↗
  • Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber RD, Piccart-Gebhart M; ALTTO Steering Committee and Investigators. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). Eur J Cancer. 2021 May;148:287-296. doi: 10.1016/j.ejca.2021.01.053. Epub 2021 Mar 23. PubMed 33765513 ↗
  • Sonnenblick A, Agbor-Tarh D, de Azambuja E, Hultsch S, Izquierdo M, Liu M, Pruneri G, Harbeck N, Piccart M, Moreno-Aspita A, Granit RZ, Rouas G, Fahoum I, Sotiriou C. STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial. Int J Cancer. 2021 Mar 15;148(6):1529-1535. doi: 10.1002/ijc.33385. Epub 2020 Nov 23. PubMed 33152119 ↗
  • Eiger D, Ponde NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Lang I, Rodeheffer RJ, Ewer MS, Suter T, de Azambuja E. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. Br J Cancer. 2020 May;122(10):1453-1460. doi: 10.1038/s41416-020-0786-x. Epub 2020 Mar 16. PubMed 32203207 ↗
  • Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber RD; ALTTO Trial Study Team. Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial. Ann Oncol. 2019 Sep 1;30(9):1507-1513. doi: 10.1093/annonc/mdz195. PubMed 31240310 ↗
  • McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat. 2014 Feb;143(3):485-92. doi: 10.1007/s10549-013-2827-0. Epub 2014 Jan 7. PubMed 24395109 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2007 to primary completion in Dec 2013, 78 months.

Results were first posted in Aug 2014, 8 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 78 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2007
First posted
Jun 22, 2007
StartActual
May 16, 2007
Primary completionActual
Dec 6, 2013
CompletionActual
Jul 1, 2021
Results first posted
Aug 18, 2014
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00490139
Collaborators
North Central Cancer Treatment Group, National Cancer Institute (NCI), Breast International Group, Canadian Cancer Trials Group
Responsible party
Sponsor
First posted
Jun 22, 2007
Start date
May 16, 2007
Primary completion
Dec 6, 2013
Completion
Jul 1, 2021
Results posted
Aug 18, 2014
Last update
Mar 21, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lapatinib · Trastuzumab

Start the discussion